PTEN and diffuse large B-cell lymphoma: Scuoppo et al. described that PTEN suppression and PI3K activation induced resistance to dasatinib, a multi-kinase inhibitor, in a model with multiple genetically characterized DLBCL cell lines in the presence of PTEN mutations [11].